In a phase 2 trial, an investigational drug that inhibits aldosterone synthase significantly lowered albuminuria in patients with or without type 2 diabetes. PHILADELPHIA—A novel selective aldosterone ...

Current screening guidelines may not capture all cases of hyperaldosteronism among patients with ESKD. Hyperaldosteronism occurs in a higher proportion of patients with end-stage kidney disease (ESKD) ...

Boston, MA - A new analysis of participants in the Framingham Offspring study has shown that aldosterone levels at the high end of normal appear to predispose people to hypertension [1]. Reporting ...

These tumors, known as adenomas, produce a hormone called aldosterone that raises blood pressure and can cause other cardiovascular problems. Adrenal tumors include nonfunctional adenomas (NFAs), ...

Current treatment options for primary aldosteronism are limited to surgery or mineralocorticoid receptor antagonists when surgery isn't an option. In a phase IIa trial, baxdrostat resolved or reduced ...

Please provide your email address to receive an email when new articles are posted on . Dysregulated aldosterone production, sometimes driven by obesity, can cause hypertension. Targeted therapies ...

A highly selective aldosterone synthase inhibitor, lorundrostat, showed promise for blood pressure reduction in a double-blind randomized phase IIb trial. Participants with uncontrolled and otherwise ...

Once-daily treatment with the selective aldosterone synthase inhibitor lorundrostat (Mineralys Therapeutics) safely and significantly reduced blood pressure in adults with uncontrolled hypertension in ...

Aldosterone acts as a mediator of hypertension, heart failure and kidney disease, and aldosterone synthase inhibitors (ASIs) have emerged as an alternative approach for the treatment of some of these ...

Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat, an aldosterone synthase inhibitor, significantly decreased automated office systolic BP ...